Gelteq (GELS)

Its technology is aimed at prescription drugs, over-the-counter products, nutraceuticals, sports nutrition, pet care and related wellness categories. Gelteq’s platform supports the formulation of gels that can carry active ingredients in measured doses, giving brand owners a potential alternative to conventional pills, powders and chews. The company’s work includes formulation development, product testing and the application of patent-pending approaches for multi-ingredient dosage forms.

Gelteq operates primarily as a business-to-business partner rather than a consumer brand. It seeks to license its delivery technology to pharmaceutical, supplement, pet health and consumer health companies that can commercialise finished products under their own labels. The company also manufactures certain existing white label products under licence, allowing partners to bring gel-based formats to market without building the technology internally.

For investors, Gelteq represents exposure to a specialised segment of drug and nutraceutical delivery rather than to a single therapeutic product. Its prospects depend on the adoption of gel formats by commercial partners, regulatory and quality requirements in each product category, and its ability to prove that its delivery systems offer practical advantages in usability, formulation flexibility and consumer acceptance.